Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
| dc.contributor.author | Sezer, A. | |
| dc.date.accessioned | 2022-08-03T11:47:14Z | |
| dc.date.available | 2022-08-03T11:47:14Z | |
| dc.date.issued | 2021 | |
| dc.identifier.endpage | S951 | en_US |
| dc.identifier.issn | 1556-0864 | en_US |
| dc.identifier.issue | 10 | en_US |
| dc.identifier.startpage | S951 | en_US |
| dc.identifier.uri | http://hdl.handle.net/11727/7216 | |
| dc.identifier.volume | 16 | en_US |
| dc.identifier.wos | 000709606500217 | en_US |
| dc.language.iso | eng | en_US |
| dc.relation.journal | JOURNAL OF THORACIC ONCOLOGY | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Randomised Controlled Trials | en_US |
| dc.subject | Phase II and III Clinical Trials | en_US |
| dc.subject | Immune checkpoint inhibitors | en_US |
| dc.title | Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1 | en_US |
| dc.type | Conference Object | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: